CroíValve Announces the Appointment of Jaime Wheeler as Chief Executive Officer

DUBLIN--(BUSINESS WIRE)--Jul 28, 2026--

CroíValve, a clinical-stage medical device company developing the DUO™ transcatheter tricuspid coaptation valve system, today announced the appointment of Jaime Wheeler, MBA, CPhT, as Chief Executive Officer. In conjunction with this, Lucy O’Keeffe will transition into the role of Chief Operating Officer where she will support Jaime in delivering CroíValve’s mission of innovating a better way to treat tricuspid regurgitation (TR). Jaime is a transformational healthcare executive with more than 25 years of experience driving innovation at the intersection of clinical excellence and business strategy. Previously, Jaime served as the Senior Vice President of Global Clinical Affairs, Transcatheter Heart Valves at Edwards Lifesciences. There, she was instrumental in bringing multiple breakthrough therapies to market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728639143/en/

CroíValve recently announced the expansion of its TANDEM II study, a US and EU based prospective, multicenter study to evaluate the safety and performance of the DUO™ Adapt System in patients with severe or greater symptomatic TR.

Bernard Collins, Chairman of CroíValve, commented: “ Jaime brings a proven track record in guiding innovative technologies to market, along with leading high-performing teams. Her leadership will be hugely beneficial in guiding the company through its commercialization journey ahead as we expand our US base and global activities. I would like to thank Lucy, on behalf of the board of directors, for her dedication in leading CroíValve successfully through development and initial clinical validation, demonstrating the value proposition of the DUO System. ”

Jaime Wheeler, newly appointed CEO, commented: “ What drew me to CroíValve is the caliber of the team and the strength of the science behind the DUO System. I've built my career on bringing challenging, innovative technologies to patients, and I'm looking forward to doing that here, for our investors and, more importantly, for the patients living with tricuspid regurgitation."

Lucy O’Keeffe, newly appointed COO, former CEO and Board member, added: “ AsCroíValve looks towards commercialization, it is the appropriate time to bring in a leader with the right experience for this next phase. Jaime’s exceptional track record of successfully bringing novel transcatheter devices to market is a tremendous asset forCroíValve. I am thrilled to collaborate with her as we embark on this exciting next chapter, accelerating our mission to deliver the DUO System to the patients who need it most. ”

About Jaime

Jaime brings more than 25 years of medical device and pharmaceutical leadership, deep clinical research expertise across Cardiology and Structural Heart, and a track record of guiding innovative technologies to market. She has managed multiple divisions and regions, including an expatriate assignment in Tokyo, Japan, and served as clinical lead on multiple successful mergers and acquisitions during her career.

She joins CroíValve after 12 years at Edwards Lifesciences, most recently as Senior Vice President of Global Clinical Affairs for the Transcatheter Heart Valve business unit, where she played a pivotal role in advancing the clinical evidence that shapes transcatheter structural heart care today — most notably the PARTNER trial series. Beyond her research leadership, she is a strong advocate for patient access, representation, and health equity, and has held active roles in industry and community leadership.

Jaime holds a Bachelor of Science degree from Virginia Tech and a Master of Business Administration from Florida Atlantic University. She is a former Virginia State Emergency Medical Technician (EMT-B) and a Certified Pharmacy Technician (CPhT). She is an active member of AdvaMed, MDEpiNet, MedTech Color, and Girls Inc. of Orange County, among other nonprofit and philanthropic organizations.

About CroíValve

CroíValve is a clinical stage medical device company focused on the development of a novel transcatheter device for the treatment of tricuspid regurgitation with Research, Development & Operations based in Ireland and Clinical & Regulatory based in the US. Caution: The DUO™ System is an investigational device and not for sale in any geography.

Jaime Wheeler, Chief Executive Officer, CroíValve

WASHINGTON (AP) — President Donald Trump and Ukrainian President Volodymyr Zelenskyy will meet Tuesday ahead of Sen. Lindsey Graham's funeral, their second sit-down this month and after a far-right activist with the U.S. president’s ear had a widely publicized change of heart on Russia’s war against Ukraine.

Trump is set to welcome Zelenskyy to the White House as the Ukrainian leader travels to Washington to honor Graham, whose final act as a public official was visiting Kyiv and securing an agreement on a package of sanctions that seek to punish countries that purchase Russian oil, gas and other exports.

But Zelenskyy is now being bolstered by an unusual source: Laura Loomer, known primarily for her incendiary social media posts and her influence with the president. Traveling through Ukraine, Loomer has witnessed Moscow’s barrage firsthand and interviewed Zelenskyy while admitting she was “bamboozled by Russian propaganda.”

Loomer said she spoke to Trump after she met with Zelenskyy in Ukraine last week, and she also expects to meet with the U.S. president once she returns from her trip.

“It’s looking good for Ukraine, right?” Loomer said during an interview with The Associated Press. “Going into this meeting next week at the Oval Office is looking pretty good.”

Ahead of the meeting, Zelenskyy has also warned that Russia has been aiding Iran as the war persists by capturing satellite imagery of U.S. bases in the Gulf region that later appear in Iran. The Ukrainian president also asserted that there was a “clear correlation” between Russia’s images and subsequent Iranian strikes.

“The purpose is clear,” Zelenskyy said earlier this month. “None of us in the world should turn a blind eye to one very simple fact: Evil always seeks ways to make things worse and spread further.”

On Monday, Trump downplayed any impact of potential Russian assistance for Iran.

“I don’t think they’ve been doing it, certainly not at a high level,” Trump told reporters on Air Force One as he traveled to Michigan. “And if they have, it has been very un-impactful.”

Still, he said he would raise the issue with Russian President Vladimir Putin.

Zelenskyy has a busy itinerary during his latest visit to Washington. In addition to his White House meeting, Zelenskyy will head to the Capitol to meet with senators on Tuesday evening after Graham’s funeral at Washington National Cathedral, according to a person with knowledge of the meeting who was not authorized to discuss it publicly and spoke on condition of anonymity.

Republican leadership is hoping to advance Graham’s sanctions legislation this week, although the Senate is juggling several other priorities before lawmakers leave Washington for the August recess.

The bill has dozens of backers from both parties and is seen as the main policy tribute to Graham, who died unexpectedly this month from a tear in his aorta. It imposes tariffs on goods from the world’s top five purchasers of Russia oil or natural gas, including China and India.

The legislation also includes sanctions against Putin, senior Russian political and military leaders, and Russian financial institutions and energy projects.

Trump met with Zelenskyy on the sidelines of the NATO summit earlier this month in Ankara, Turkey, and announced that the U.S. will give Ukraine a license to make Patriot air defense systems, a long-running request from Kyiv in order to counter Russian missile attacks.

The air defense systems are expensive to make and are in high demand. Noting that he and Zelenskyy have “actually developed a good relationship,” Trump said the U.S. will help Ukraine produce the Patriots and that the country would be able to produce them “pretty quickly.”

In this photo provided by the Ukrainian Presidential Press Office, Laura Loomer, right, interviews Ukrainian President Volodymyr Zelenskyy Thursday July 23, 2026, in Kyiv, Ukraine. (Ukrainian Presidential Press Office via AP)

FILE - Ukraine's President Volodymyr Zelenskyy looks od during his meeting with U.S. President Donald Trump on the sidelines of the NATO summit in Ankara, Turkey, on July 8, 2026. (AP Photo/Alex Brandon, File)